91224-37-2

91224-37-2 structure

Name: Spantide I TFA
Chemical Name: (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P
CAS Number: 91224-37-2
Molecular Formula: C₇₅H₁₀₈N₂₀O₁₃
Molecular Weight: 1497.79000
Catalog: Signaling Pathways GPCR/G Protein Neurokinin Receptor
Create Date: 2016-02-14 07:38:01
Modify Date: 2024-01-09 21:39:34
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].

Name	(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P
Synonyms	M.W. 1497.80 C75H108N20O13 SPANTIDE 1-Arg-7,9-Trp-11-Leu-substance p SPANTIDE HYDROCHLORIDE Spantide I Substance P-[D-Arg1,D-Trp7,9,Leu11]

Description	Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor
Target	NK1:230 nM (Ki) NK2:8150 nM (Ki)
In Vivo	Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals[2]. Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β[3]. Animal Model: Female, 8-week-old C57BL/6 (B6) and BALB/c mice[3]. Dosage: 36 μg/mouse. Administration: IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). Result: At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.
References	[1]. J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800. [2]. M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. [3]. Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807.

Molecular Formula	C₇₅H₁₀₈N₂₀O₁₃
Molecular Weight	1497.79000
Exact Mass	1496.84000
PSA	548.21000
LogP	7.06100
Storage condition	-20°C

91224-37-2	122752-15-2
143868-20-6	117442-28-1
50939-54-3	12125-21-2
1858223-95-6	1309353-37-4
635-94-9	1202947-60-1